Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for Steroid Withdrawal in Rheumatoid Arthritis
NCT04927000Phase 4Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tofacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Disease Remission (DAS28 < 2.6) at 1 year and Successful Glucocorticoid Withdrawal at 1 year. Status: unknown.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04927000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927000.